Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global pertussis market was valued at US$ 6.7 billion in 2022 and is expected to register a revenue CAGR of 4.6% to reach US$ 10.2 billion by 2031.

Pertussis Market Fundamentals                                                                          

Pertussis, often known as whooping cough, is a highly infectious upper respiratory illness. It frequently causes prolonged and repetitive coughing fits. Coughing can last weeks or even months after patients notice signs of sickness. Pertussis is caused by the bacterium Bordetella pertussis. When germs invade the respiratory system, the disease begins. They cling to the cilia, which are small hair-like projections on the lining of the respiratory system. Then they emit toxins, which harm the cilia and cause airways to enlarge. 

The symptoms of pertussis usually develop within 5 to 10 days after exposure to the bacteria and may last for several weeks. Early symptoms are similar to the common cold, including a runny nose, low-grade fever, and mild cough. As the disease progresses, the cough becomes more severe and may become a series of rapid coughs followed by a high-pitched “whoop” sound when the person tries to breathe in. The DTP, DTaP, and TDaP vaccinations provide prophylactic therapy for pertussis. There are several vaccinations available on the market for various age groups. Adults and pregnant women can use Adacel and Boostrix. Post-exposure therapy is also available on the Pertussis market in macrolides (erythromycin, clarithromycin, or azithromycin) and Trimethoprim-sulfamethoxazole.

[756765]

Pertussis Market Dynamics

Despite the availability of vaccines, pertussis remains a significant health concern worldwide. In recent years, there has been an increase in reported pertussis cases globally, driving the demand for pertussis treatment and prevention. As awareness about pertussis increases among healthcare providers and the general public, more cases are being diagnosed and treated. This trend is expected to continue, further driving the demand for pertussis treatment. Several companies are developing new, improved pertussis vaccines that offer greater efficacy and longer-lasting protection. This trend is expected to drive revenue growth in the pertussis market as healthcare providers and patients seek the most effective and safe vaccines. As healthcare spending increases globally, there is a greater focus on preventing and treating infectious diseases like pertussis. This trend is expected to drive revenue growth in the pertussis market as governments and healthcare providers invest in new treatments and vaccines. The aging population is more susceptible to pertussis and other respiratory diseases. As the global population ages, the demand for pertussis treatment and prevention will increase.

Many people are not aware of the seriousness of the disease. This can lead to low vaccine demand. The cost of pertussis vaccines can be prohibitive for some populations, particularly in low-income countries. This can limit access to vaccines and increase the risk of outbreaks. In some regions, vaccine hesitancy is a significant barrier to vaccination programs. Vaccine safety and efficacy information can encourage individuals to vaccinate, leading to pertussis outbreaks. The pertussis bacterium is known to mutate rapidly, leading to new strains that may be more virulent or resistant to existing vaccines. This can make it challenging to develop effective vaccines and maintain protection against the disease. Pertussis is more prevalent in some regions than others, making it challenging to develop effective vaccination strategies and allocate resources to where they are needed most.

Pertussis Market Ecosystem

The global pertussis market is analyzed from the following perspectives: treatment, patient type, and region. 

Pertussis Market by Treatment

[856756] 

based on treatment, the global pertussis market is segmented into immunization and antibiotics.

The immunization segment dominates the global pertussis market with the largest revenue share because vaccination is one of the most effective ways to prevent pertussis. Immunization against pertussis is recommended for all infants, children, and adults who have not been vaccinated or require a booster shot. The high coverage rate of pertussis immunization programs in developed countries has significantly reduced the incidence of pertussis. In addition, the increasing awareness of the importance of vaccination and the expansion of vaccination programs in developing countries are driving the revenue growth of the immunization segment in the pertussis market. The availability of different types of pertussis vaccines, such as acellular and whole-cell pertussis vaccines, also contributes to the immunization segment’s revenue growth. Acellular pertussis vaccines are generally preferred over whole-cell ones due to their better safety profile and efficacy. However, whole-cell pertussis vaccines are still used in some countries where acellular pertussis vaccines are not available or affordable. Moreover, introducing new and improved pertussis vaccines, such as combined vaccines that protect against multiple diseases, is expected to drive the revenue growth of the immunization segment in the pertussis market. For instance, the combination of pertussis vaccine with diphtheria and tetanus vaccines is commonly used in many countries to prevent multiple diseases through a single vaccine.

The antibiotics segment accounts for a significant revenue share of the global pertussis market because antibiotics are the primary treatment option for pertussis, also known as whooping cough. Pertussis is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis, and antibiotics are used to treat the infection and prevent its spread to others. Antibiotics, such as azithromycin, clarithromycin, and erythromycin, are commonly prescribed to treat pertussis. They work by killing the bacteria that cause the infection, reducing the severity and duration of symptoms, and preventing complications. The widespread use of antibiotics to treat pertussis has contributed to the revenue growth of the antibiotics segment in the global market. As pertussis remains a prevalent respiratory infection worldwide, the demand for antibiotics to treat the disease will likely continue to drive this segment’s revenue growth.

Pertussis Market by Patient Type

Based on the patient type, the global pertussis market is segmented into pediatric and adults.

The pediatric segment dominates the global pertussis market because pertussis is most common in infants and young children, particularly those too young to have completed the full course of vaccinations. Infants are also at the greatest risk of severe complications and death from pertussis. Immunization against pertussis is recommended for all infants and young children. The first dose is typically given at two months, followed by additional doses at 4 and 6 months, and booster doses at 15-18 months and 4-6 years of age. The high coverage rate of pertussis immunization programs in developed countries has significantly reduced the incidence of pertussis in infants and young children. In underdeveloped countries, where pertussis vaccination coverage may be lower, infants and young children remain at a higher risk of contracting pertussis. Additionally, introducing new and improved pertussis vaccines, such as combined vaccines that protect against multiple diseases, is expected to drive the revenue growth of the infant segment in the pertussis market. The use of combination vaccines is particularly important in infants and young children, as it reduces the number of injections required and improves overall vaccine coverage rates.

The adult segment accounts for a notable revenue share of the global pertussis market, affecting people of all ages. Pertussis is often underdiagnosed and underreported in adults, leading to a significant disease burden in this population. Adults contracting pertussis can experience severe and prolonged coughing fits, leading to complications such as pneumonia, rib fractures, and even hospitalization. As a result, healthcare providers increasingly recognize the importance of diagnosing and treating pertussis in adults, driving the growth of the market revenue in the adult segment. Furthermore, the increasing awareness of pertussis among adults and the availability of pertussis vaccines and diagnostic tests have contributed to the growth of the pertussis market revenue in the adult segment. Adults at high risk of contracting pertussis, such as healthcare workers, parents, and grandparents of young children, are increasingly targeted for pertussis vaccination and diagnosis, leading to the growth of segment’s revenue share.

Pertussis Market by Region

Based on the region, the global pertussis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The North American market revenue for pertussis is dominated primarily due to factors such as higher awareness levels, greater adoption of advanced diagnostic techniques, and favorable government initiatives to control and prevent the spread of the disease. One of the main reasons North America’s dominance in the pertussis market is the high level of awareness among healthcare providers and the general population about the severity and consequences of the disease. This awareness has increased the demand for advanced diagnostic techniques and treatments in the North American market. Moreover, North America has a well-established healthcare system with high technological advancements and infrastructure. This allows for the efficient diagnosis and treatment of pertussis cases, further contributing to the dominance of the North American market revenue share. Furthermore, the governments of North American countries have implemented several initiatives to control and prevent the spread of pertussis. These initiatives include vaccination programs and public education campaigns to increase awareness about the disease and its prevention. 

Asia Pacific accounts for a significant revenue share of the global pertussis market due to several factors. Firstly, the region has a high burden of pertussis cases, particularly in densely populated countries such as India and China. This has resulted in high demand for pertussis diagnostics and treatments in the region, driving the market’s revenue growth. Secondly, the increasing awareness about the disease and its consequences among the general population and healthcare professionals has led to an increased diagnosis and treatment of pertussis in the region. This has further fueled the regional revenue growth. Moreover, the rising investment in healthcare infrastructure in the region has increased the availability and accessibility of pertussis vaccines, antibiotics, and other treatment options, driving the market’s revenue growth. Additionally, favorable government initiatives and policies aimed at promoting vaccination and controlling the spread of pertussis have also contributed to the revenue growth of the pertussis market in the region. 

Competitive Landscape

The prominent players operating in the global pertussis market are:

• GlaxoSmithKline Plc.
• Pfizer Inc.
• Sanofi S.A.
• Merck & Co. Inc. 
• Novartis AG
• ILiAD Biotechnologies LLC
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Ltd.
• Astellas Pharma Inc.
• Panacea Biotec Ltd.

Strategic Development

• On 6TH September 2022, IliAD Biotechnologies, LLC (IliAD), a clinical-stage biotech firm creating the world’s most advanced next-generation pertussis vaccine, announced the completion of a $42.8 million Class D round of funding. These funds allowed the organization to launch a Phase 2b Human Challenge trial to investigate if BPZE1 immunization inhibits colonization from wild-type Bordetella pertussis infection.

Frequently Asked Questions About This Report